C9453 HCPCS Level II code: Injection, nivolumab, 1 mg
CMS terminated C9453: its last date of service was Dec 31, 2015. It stays here for looking up older claims; newer services need a current code.
Official description
C9453Injection, nivolumab, 1 mg
Short description: Injection, nivolumab
HCPCS · United States
Medicare details
The indicators CMS publishes with C9453 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Special coverage instructions apply
- Medicare pricing
- Statute
- Type of service
- Other medical items or services; Ambulatory surgical center (facility usage for surgical services)
- BETOS category
- Chemotherapy
- Coverage statute
- 1833(t)
- Cross-reference
- See J9299
- Added
- Jul 1, 2015
- Terminated after
- Dec 31, 2015
Where C9453 sits
- 1C codesOutpatient prospective payment system
- 2Terminated C9453Injection, nivolumab, 1 mg
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
Is HCPCS code C9453 still valid?
No. CMS terminated C9453; its last date of service was Dec 31, 2015. It is listed for looking up services from before then. Use a current code for newer services.
Does Medicare cover C9453?
CMS lists C9453’s Medicare coverage as “Special coverage instructions apply” and its pricing as “Statute”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside C9453
All C codesC9447Injection, phenylephrine and ketorolac, 4 ml vialC9448Netupitant 300 mg and palonosetron 0.5 mg, oralC9449Injection, blinatumomab, 1 mcgC9450Injection, fluocinolone acetonide intravitreal implant, 0.01 mgC9451Injection, peramivir, 1 mgC9452Injection, ceftolozane 50 mg and tazobactam 25 mgC9454Injection, pasireotide long acting, 1 mgC9455Injection, siltuximab, 10 mgC9456Injection, isavuconazonium sulfate, 1 mgC9457Injection, sulfur hexafluoride lipid microsphere, per mlC9458Florbetaben f18, diagnostic, per study dose, up to 8.1 millicuriesC9459Flutemetamol f18, diagnostic, per study dose, up to 5 millicuries